Company Overview of ACCU-BREAK Pharmaceuticals, Inc.
ACCU-BREAK Pharmaceuticals, Inc. develops and licenses pharmaceutical tablet technologies. The company offers bi-layer and tri-layer technologies, which are used to create tablets that are dividable by hand into accurate partial/smaller doses for patients to adjust their dose. Its technologies are used for single drug products, fixed and split combination drug products, standard and controlled release formulations, and incompatible drugs in human and veterinary medicines. The company has a strategic alliance agreement with Azopharma Development Group. ACCU-BREAK Pharmaceuticals, Inc. was formerly known as SoLapharm, Inc. and changed its name to ACCU-BREAK Pharmaceuticals, Inc. in April 2006....
1000 South Pine Island Road
Plantation, FL 33324
Founded in 2001
Key Executives for ACCU-BREAK Pharmaceuticals, Inc.
President and General Counsel
Executive Chairman of the Board
Co-Founder, Vice President of Regulatory & Technical Affairs and Director
Compensation as of Fiscal Year 2016.
ACCU-BREAK Pharmaceuticals, Inc. Key Developments
Accu-Break Pharmaceuticals Files NDA with US FDA for Unique Anticoagulant Frequently Split Tablets Warfarin Potassium
Nov 20 15
Accu-Break Pharmaceuticals has filed its 505(b)(2) New Drug Application (NDA) for anticoagulant Warfarin Potassium with the US Food & Drug Administration (FDA). The company said the 4 mg tablet splits into exact 1 mg quarter doses, while the 5 mg tablet provides half doses. Based on IMS Data, the company believes that these two tablets address essentially all of the currently available 9 Coumadin doses. The ABP bilayer tablet technology with its backbone drug-free layer enables accurate dose adjustments of a drug that exhibits an extremely narrow therapeutic index. Along with Alembic Pharmaceuticals, the company has developed Warfarin Potassium and will manufacture the product. Both companies are seeking licensees in the US and worldwide.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries